Aflibercept may be beneficial for AMD

Article

Aflibercept 2.0 mg may be beneficial for cases of exudative AMD unsuccessfully treated with ranibizumab or bevacizumab, according to a recent retrospective review.

Aflibercept 2.0 mg may be beneficial for cases of exudative AMD unsuccessfully treated with ranibizumab or bevacizumab, according to a recent retrospective review.

Dr Jeffrey S. Heier, Department of Retina, Ophthalmic Consultants of Boston, Massachusetts, USA, evaluated the anatomic and visual effect of intravitreal aflibercept 2.0 mg in cases of exudative AMD with persistent fluid on OCT. Each patient has already received ranibizumab 0.5 mg and/or bevacizumab 1.25 mg at one and six months.

The group collected tabulated data on 353 eyes. This included details of prior treatments, best available visual acuity, central subfoveal thickness on registered SD-OCT before and after aflibercept injection centred on the anatomic fovea and macular description before and after aflibercept injection.

Of the total eyes studied, 28 presented with persistent fluid after a mean of 20 regular ranibizumab/bevacizumab injections. Anatomic improvement was noted in 89% of eyes at one month after just one aflibercept injection.

Even though visual acuity did not improve at either the one-month follow-up or the six months follow-up, central subfoveal thickness improved from 295 to 272 microns and 18% of eyes were dry after a single aflibercept injection.

After a mean of 4.4 aflibercept injections over six months the central subfoveal thickness remained lower, with 64% of eyes demonstrating anatomic improvement and 25% of eyes were determined as dry.

Please visit the British Journal of Ophthalmology to read the abstract.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.